NH Nonghyup Life announced on the 6th that it has launched the 'Saeronaon NH Cancer Insurance,' which provides targeted anticancer drug approval treatment funds.
[Asia Economy Reporter Oh Hyung-gil] NH Nonghyup Life announced on the 6th that it has launched the 'New NH Cancer Insurance,' which supports targeted anticancer drug approval treatment funds.
It provides support of up to 50 million KRW for targeted anticancer drug approval treatment funds that selectively attack the growth and spread of cancer cells. Small cancers classified as minor cancers under the main contract, such as thyroid cancer and prostate cancer, are also covered through mandatory additional special contracts.
When subscribing to 10 million KRW each for the main contract and minor cancer diagnosis special contract, payments of 10 million KRW for thyroid cancer, 6 million KRW for prostate cancer, and 3 million KRW (each for the first occurrence only) for other skin cancers, colon mesothelioma, carcinoma in situ, and borderline tumors are provided.
In addition to the diagnosis insurance payment upon general cancer diagnosis, the total premiums already paid for the main contract are refunded. For the non-renewable main contract, a special contract can be selected that refunds the total premiums paid during the payment period for diagnosis of two major diseases (cerebral hemorrhage and acute myocardial infarction).
If the re-diagnosis cancer coverage special contract is subscribed, additional insurance payments are made upon cancer re-diagnosis after two years from the initial diagnosis. Even if the cancer is not cured, cancer diagnosis benefits can be continuously received every two years until complete recovery.
Those with pre-existing conditions who were previously unable to subscribe due to hypertension, diabetes, or cancer treatment history can now easily enroll. Subscription is possible if there are no applicable items among three disclosure items: doctor's opinion on hospitalization, surgery, or additional tests within 3 months; hospitalization or surgery within 2 years; and cancer diagnosis within 5 years.
The subscription age ranges from a minimum of 15 to a maximum of 75 years. The subscription limit is up to 30 million KRW in units of 10 million KRW based on the main contract. The premium for a subscription amount of 10 million KRW, electric payment, 20-year maturity, age 40, Type 1 (renewable), general subscription pure protection type is 6,200 KRW for males and 6,700 KRW for females.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
